Colorectal Cancer

According to findings from a four-arm phase III NSABP R-04 trial, single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.

The development of predictive biomarkers is widely accepted as an important milestone in the move toward personalized, or precision, medicine and the ability to identify the right drug for the right patient. JTT interviewed Kopetz about biomarker models.

In September 2012, the FDA approved regorafenib for treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, with an anti-EGFR therapy.

Recent biomarker analyses of studies involving the anti-EGFR antibody panitumumab combined with chemotherapy for treatment of mCRC have advanced clinicians’ ability to prospectively identify patients who are, more or less, likely to respond to this agent.

A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival (OS) and progression-free survival (PFS) in favor of aflibercept plus FOLFIRI in patients with mCRC.

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

S. Gail Eckhardt, MD, discusses the role of regorafenib in colorectal cancer.

S. Gail Eckhardt, MD, discusses the role of angiogenesis inhibitors for the treatment of metastatic colorectal cancer (mCRC), following the approval of aflibercept.

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

S. Gail Eckhardt, MD, Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

Frontline cetuximab plus FOLFIRI improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wildtype metastatic colorectal cancer.

Data from the French National Cancer Institute showed an increase in testing for BRCA1/2 for breast and ovarian cancer, though not for the MMR mutation for Lynch syndrome.

Volker Heinemann, MD, PhD, professor, medical oncology, University of Munich in Munich, Germany, discusses the design and results from the FIRE-3 trial at the 2013 ASCO Annual Meeting.